Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Amgen reported impressive progress across its product lines in Q4. The standout performer was Repatha, whose sales increased ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Amgen reported impressive progress across its product lines in Q4. The standout performer was Repatha, whose sales increased 45% year over year to $606 million thanks to effective volume growth ...

Gladstone Institutional Advisory LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.9% in the fourth ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.